Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years


Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.

Related Videos
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
Related Content
© 2023 MJH Life Sciences

All rights reserved.